2010
Cost evaluation of evidence-based treatments.
Sindelar JL, Ball SA. Cost evaluation of evidence-based treatments. Addiction Science & Clinical Practice 2010, 5: 44-51. PMID: 22002453, PMCID: PMC3120119.Peer-Reviewed Original Research
2007
Clinic Variation in the Cost‐Effectiveness of Contingency Management
Olmstead TA, Sindelar JL, Petry NM. Clinic Variation in the Cost‐Effectiveness of Contingency Management. American Journal On Addictions 2007, 16: 457-460. PMID: 18058410, PMCID: PMC3072219, DOI: 10.1080/10550490701643062.Peer-Reviewed Original ResearchCost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysis
2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment Outcome
2004
Value to smokers of improved cessation products: Evidence from a willingness-to-pay survey
Busch S, Falba T, Duchovny N, Jofre-Bonet M, O'Malley S, Sindelar J. Value to smokers of improved cessation products: Evidence from a willingness-to-pay survey. Nicotine & Tobacco Research 2004, 6: 631-639. PMID: 15370159, DOI: 10.1080/14622200410001727885.Peer-Reviewed Original ResearchMeSH KeywordsAdultCost-Benefit AnalysisFemaleFinancing, PersonalHealth Care CostsHealth SurveysHumansMaleMiddle AgedMotivationSmokingSmoking CessationConceptsSmoking cessation productsSmoking cessationCessation productsCessation treatmentEffective smoking cessation treatmentsWeight gainTobacco cessation treatmentSmoking cessation treatmentPresent studyClinical trialsEffective treatmentBaseline surveyCessationTreatmentNew HavenMedicationsSmokersTrialsCost effectiveness of disulfiram Treating cocaine use in methadone-maintained patients
Jofre-Bonet M, Sindelar JL, Petrakis IL, Nich C, Frankforter T, Rounsaville BJ, Carroll KM. Cost effectiveness of disulfiram Treating cocaine use in methadone-maintained patients. Journal Of Substance Use And Addiction Treatment 2004, 26: 225-232. PMID: 15063917, PMCID: PMC3662046, DOI: 10.1016/s0740-5472(04)00004-2.Peer-Reviewed Original ResearchConceptsMethadone treatmentClinical trialsCocaine useDouble-blind clinical trialCocaine dependenceStandard methadone treatmentBlind clinical trialMethadone-maintained patientsRandomized clinical trialsOpioid-dependent subjectsMethadone-maintained opiate addictsStandard treatmentOutcome measuresOpioid addictsPromising treatmentOpiate addictsIncremental costDisulfiramAdditional treatmentNumber of daysTrialsTreatmentCost effectivenessEconomic evaluationAddicts
2002
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
French MT, Salomé HJ, Sindelar JL, McLellan AT. Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI. Health Services Research 2002, 37: 433-455. PMID: 12036002, PMCID: PMC1430361, DOI: 10.1111/1475-6773.031.Peer-Reviewed Original ResearchConceptsDrug Abuse Treatment Cost Analysis ProgramBenefit-cost analysisEconomic evaluationEconomic benefitsFuture economic researchTotal economic benefitTotal economic costFuture economic evaluationsEconomic researchDetailed methodological guidelinesEmpirical applicationConsecutive fiscal yearsSensitivity analysisOutpatient drug-free programsEconomic costsMethodological guidelinesFiscal yearCost dataSubsequent sensitivity analysisDrug-free programsResource useMethodological foundationsBenefitsCostEstimates
1991
Economic cost of illicit drug studies: critique and research agenda.
Sindelar JL. Economic cost of illicit drug studies: critique and research agenda. NIDA Research Monograph 1991, 113: 33-45. PMID: 1762641.Peer-Reviewed Original Research